Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).

Lopez CL, Joos B, Bartsch DK, Manoharan J, Albers M, Slater EP, Bollmann C, Roth S, Bayer A, Fendrich V.

World J Surg. 2019 Mar;43(3):831-838. doi: 10.1007/s00268-018-4839-8.

PMID:
30600364
2.

Familial Pancreatic Cancer.

Benzel J, Fendrich V.

Oncol Res Treat. 2018;41(10):611-618. doi: 10.1159/000493473. Epub 2018 Sep 28.

PMID:
30269130
3.

[Minimal Invasive Surgery of Adrenal Tumors].

Fendrich V, Knecht M.

Dtsch Med Wochenschr. 2018 Aug;143(17):1235-1241. doi: 10.1055/a-0637-7360. Epub 2018 Aug 22. Review. German.

PMID:
30134455
4.

Chemoprevention with Enalapril and Aspirin in Men1(+/T) Knockout Mouse Model.

Manoharan J, Fendrich V, Di Fazio P, Bollmann C, Roth S, Joos B, Mintziras I, Albers MB, Ramaswamy A, Bertolino P, Zhang CX, Slater EP, Bartsch DK, Lopez-Lopez CL.

Neuroendocrinology. 2018;107(3):257-266. doi: 10.1159/000492224. Epub 2018 Jul 19.

PMID:
30025403
5.

Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature.

Benzel J, Fendrich V.

Digestion. 2018;97(4):275-287. doi: 10.1159/000485741. Epub 2018 Mar 27. Review.

6.

Expression of neuropeptide Y and its receptors Y1 and Y2 in pancreatic intraepithelial neoplasia and invasive pancreatic cancer in a transgenic mouse model and human samples of pancreatic cancer.

Waldmann J, Fendrich V, Reichert M, Hecker A, Bartsch DK, Padberg W, Holler JPN.

J Surg Res. 2018 Mar;223:230-236. doi: 10.1016/j.jss.2017.11.010. Epub 2017 Dec 22.

PMID:
29433879
7.

Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury.

Fendrich V, Jendryschek F, Beeck S, Albers M, Lauth M, Esni F, Heeger K, Dengler J, Slater EP, Holler JPN, Baier A, Bartsch DK, Waldmann J.

Oncogene. 2018 Apr;37(14):1845-1856. doi: 10.1038/s41388-017-0100-4. Epub 2018 Jan 25.

PMID:
29367759
8.

Surgical Therapy of Sporadic Pancreatic Neuroendocrine Neoplasias G1/G2.

Fendrich V, Bartsch DK.

Visc Med. 2017 Oct;33(5):344-350. doi: 10.1159/000456630. Epub 2017 Oct 4. Review.

9.

[Early endocrine neoplasia of the pancreas].

Fendrich V, Bartsch DK.

Chirurg. 2018 Apr;89(4):266-273. doi: 10.1007/s00104-017-0546-5. Review. German.

PMID:
29098308
10.

Overexpression of MicroRNA miR-7-5p Is a Potential Biomarker in Neuroendocrine Neoplasms of the Small Intestine.

Heverhagen AE, Legrand N, Wagner V, Fendrich V, Bartsch DK, Slater EP.

Neuroendocrinology. 2018;106(4):312-317. doi: 10.1159/000480121. Epub 2017 Aug 19.

PMID:
28848144
11.

Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary?

Manoharan J, Raue F, Lopez CL, Albers MB, Bollmann C, Fendrich V, Slater EP, Bartsch DK.

World J Surg. 2017 Aug;41(8):2026-2032. doi: 10.1007/s00268-017-3992-9.

PMID:
28321559
12.

Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms.

Partelli S, Cirocchi R, Crippa S, Cardinali L, Fendrich V, Bartsch DK, Falconi M.

Br J Surg. 2017 Jan;104(1):34-41. doi: 10.1002/bjs.10312. Epub 2016 Oct 5. Review.

PMID:
27706803
13.

Implementation and effects of pulse-contour- automated SVV/CI guided goal directed fluid therapy algorithm for the routine management of pancreatic surgery patients.

Kratz T, Simon C, Fendrich V, Schneider R, Wulf H, Kratz C, Efe T, Schüttler KF, Zoremba M.

Technol Health Care. 2016 Nov 14;24(6):899-907.

PMID:
27434283
14.

[Analysis of patient waiting times in a polyclinic for surgery].

Meyer C, Ringler A, Bartsch DK, Fendrich V.

Chirurg. 2016 Nov;87(11):964-970. German.

PMID:
27392761
15.

Refinement of screening for familial pancreatic cancer.

Bartsch DK, Slater EP, Carrato A, Ibrahim IS, Guillen-Ponce C, Vasen HF, Matthäi E, Earl J, Jendryschek FS, Figiel J, Steinkamp M, Ramaswamy A, Vázquez-Sequeiros E, Muñoz-Beltran M, Montans J, Mocci E, Bonsing BA, Wasser M, Klöppel G, Langer P, Fendrich V, Gress TM.

Gut. 2016 Aug;65(8):1314-21. doi: 10.1136/gutjnl-2015-311098. Epub 2016 May 24.

PMID:
27222532
16.

Robotic-Assisted Approach Improves Vessel Preservation in Spleen-Preserving Distal Pancreatectomy.

Eckhardt S, Schicker C, Maurer E, Fendrich V, Bartsch DK.

Dig Surg. 2016;33(5):406-13. doi: 10.1159/000444269. Epub 2016 May 4.

PMID:
27160088
17.

Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.

Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, Bonsing BA, de Vos Tot Nederveen Cappel WH, Bergman W, Wasser M, Morreau H, Klöppel G, Schicker C, Steinkamp M, Figiel J, Esposito I, Mocci E, Vazquez-Sequeiros E, Sanjuanbenito A, Muñoz-Beltran M, Montans J, Langer P, Fendrich V, Bartsch DK.

J Clin Oncol. 2016 Jun 10;34(17):2010-9. doi: 10.1200/JCO.2015.64.0730. Epub 2016 Apr 25.

PMID:
27114589
18.

Identification of tissue-specific cell death using methylation patterns of circulating DNA.

Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, Rubertsson S, Nellgård B, Blennow K, Zetterberg H, Spalding K, Haller MJ, Wasserfall CH, Schatz DA, Greenbaum CJ, Dorrell C, Grompe M, Zick A, Hubert A, Maoz M, Fendrich V, Bartsch DK, Golan T, Ben Sasson SA, Zamir G, Razin A, Cedar H, Shapiro AM, Glaser B, Shemer R, Dor Y.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1826-34. doi: 10.1073/pnas.1519286113. Epub 2016 Mar 14.

19.

Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1.

Lopez CL, Albers MB, Bollmann C, Manoharan J, Waldmann J, Fendrich V, Bartsch DK.

World J Surg. 2016 Jul;40(7):1729-36. doi: 10.1007/s00268-016-3456-7.

PMID:
26956903
20.

[Surgical approach of gastroduodenal neuroendocrine neoplasms].

Fendrich V, Bartsch DK.

Chirurg. 2016 Apr;87(4):280-7. doi: 10.1007/s00104-015-0138-1. Review. German.

PMID:
26779647
21.

C-Reactive Protein as a New Prognostic Factor for Survival in Patients With Pancreatic Neuroendocrine Neoplasia.

Wiese D, Kampe K, Waldmann J, Heverhagen AE, Bartsch DK, Fendrich V.

J Clin Endocrinol Metab. 2016 Mar;101(3):937-44. doi: 10.1210/jc.2015-3114. Epub 2015 Dec 17.

PMID:
26678655
22.

Molecular Characterization and Pathogenesis of Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Benzel J, Fendrich V.

Eur Surg Res. 2015 Dec;55(4):352-363. Epub 2015 Oct 28.

PMID:
26505881
23.

Corrigendum: identification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1.

Schneider P, Bayo-Fina JM, Singh R, Dhanyamraju PK, Holz P, Baier A, Fendrich V, Ramaswamy A, Baumeister S, Martinez ED, Lauth M.

Nat Commun. 2015 Oct 26;6:8741. doi: 10.1038/ncomms9741. No abstract available.

PMID:
26498676
24.

Identification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1.

Schneider P, Bayo-Fina JM, Singh R, Kumar Dhanyamraju P, Holz P, Baier A, Fendrich V, Ramaswamy A, Baumeister S, Martinez ED, Lauth M.

Nat Commun. 2015 Aug 27;6:8023. doi: 10.1038/ncomms9023. Erratum in: Nat Commun. 2015;6:8741.

25.

Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.

Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G, Fave GD, Sette C.

Oncogene. 2016 Apr 21;35(16):2031-9. doi: 10.1038/onc.2015.270. Epub 2015 Aug 3.

26.

Pancreatogastrostomy Versus Pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): Perioperative and Long-term Results of a Multicenter Randomized Controlled Trial.

Keck T, Wellner UF, Bahra M, Klein F, Sick O, Niedergethmann M, Wilhelm TJ, Farkas SA, Börner T, Bruns C, Kleespies A, Kleeff J, Mihaljevic AL, Uhl W, Chromik A, Fendrich V, Heeger K, Padberg W, Hecker A, Neumann UP, Junge K, Kalff JC, Glowka TR, Werner J, Knebel P, Piso P, Mayr M, Izbicki J, Vashist Y, Bronsert P, Bruckner T, Limprecht R, Diener MK, Rossion I, Wegener I, Hopt UT.

Ann Surg. 2016 Mar;263(3):440-9. doi: 10.1097/SLA.0000000000001240.

27.

Bronchopulmonary Neuroendocrine Neoplasms and Their Precursor Lesions in Multiple Endocrine Neoplasia Type 1.

Bartsch DK, Albers MB, Lopez CL, Apitzsch JC, Walthers EM, Fink L, Fendrich V, Slater EP, Waldmann J, Anlauf M.

Neuroendocrinology. 2016;103(3-4):240-7. doi: 10.1159/000435921. Epub 2015 Jun 18.

PMID:
26113081
28.

Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases.

Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, Tamburrino D, Keck T, Caplin ME, Bartsch D, Thirlwell C, Fusai G, Falconi M.

Neuroendocrinology. 2015;102(1-2):68-76. doi: 10.1159/000431379. Epub 2015 May 29.

PMID:
26043944
29.

[Transaxillary robot-assisted thyroidectomy: First experiences with a new operation technique].

Eckhardt S, Maurer E, Fendrich V, Bartsch DK.

Chirurg. 2015 Oct;86(10):976-82. doi: 10.1007/s00104-015-0008-x. German.

PMID:
25971612
30.

Histone deacetylase 6 represents a novel drug target in the oncogenic Hedgehog signaling pathway.

Dhanyamraju PK, Holz PS, Finkernagel F, Fendrich V, Lauth M.

Mol Cancer Ther. 2015 Mar;14(3):727-39. doi: 10.1158/1535-7163.MCT-14-0481. Epub 2014 Dec 31.

31.

Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.

Geis C, Fendrich V, Rexin P, Di Fazio P, Bartsch DK, Ocker M, Quint K, Heverhagen AE.

J Surg Res. 2015 Apr;194(2):388-93. doi: 10.1016/j.jss.2014.10.052. Epub 2014 Nov 5.

PMID:
25439321
32.

Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.

Fendrich V, Wichmann S, Wiese D, Waldmann J, Lauth M, Rexin P, L-Lopez C, Schlitt HJ, Bartsch DK, Lang SA.

Neuroendocrinology. 2014;100(4):300-9. doi: 10.1159/000368610. Epub 2014 Oct 3.

PMID:
25301256
33.

CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms.

Krug S, Kühnemuth B, Griesmann H, Neesse A, Mühlberg L, Boch M, Kortenhaus J, Fendrich V, Wiese D, Sipos B, Friemel J, Gress TM, Michl P.

Endocr Relat Cancer. 2014;21(6):879-90. doi: 10.1530/ERC-14-0152. Epub 2014 Sep 23.

PMID:
25248790
34.

Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.

Bartsch DK, Slater EP, Albers M, Knoop R, Chaloupka B, Lopez CL, Fendrich V, Kann PH, Waldmann J.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2387-91. doi: 10.1210/jc.2013-4432. Epub 2014 Sep 11.

PMID:
25210877
35.

Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections.

Dieckhoff P, Runkel H, Daniel H, Wiese D, Koenig A, Fendrich V, Bartsch DK, Moll R, Müller D, Arnold R, Gress T, Rinke A.

Digestion. 2014;90(2):89-97. doi: 10.1159/000365143. Epub 2014 Sep 4.

PMID:
25196446
36.

Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors.

Fendrich V, Lopez CL, Manoharan J, Maschuw K, Wichmann S, Baier A, Holler JP, Ramaswamy A, Bartsch DK, Waldmann J.

Endocr Relat Cancer. 2014 Oct;21(5):813-24. doi: 10.1530/ERC-14-0175. Epub 2014 Aug 13.

PMID:
25121552
37.

The Yes-associated protein controls the cell density regulation of Hedgehog signaling.

Tariki M, Dhanyamraju PK, Fendrich V, Borggrefe T, Feldmann G, Lauth M.

Oncogenesis. 2014 Aug 11;3:e112. doi: 10.1038/oncsis.2014.27.

38.

The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer.

Fendrich V, Lauth M.

Expert Opin Ther Targets. 2014 Nov;18(11):1277-83. doi: 10.1517/14728222.2014.945427. Epub 2014 Jul 31. Review.

PMID:
25078025
39.

MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer.

Slater EP, Strauch K, Rospleszcz S, Ramaswamy A, Esposito I, Klöppel G, Matthäi E, Heeger K, Fendrich V, Langer P, Bartsch DK.

Transl Oncol. 2014 Aug;7(4):464-71. doi: 10.1016/j.tranon.2014.05.007. Epub 2014 Jun 21.

40.

Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.

Knoop RF, Sparn M, Waldmann J, Plassmeier L, Bartsch DK, Lauth M, Hudemann C, Fendrich V.

Neoplasia. 2014 Jun;16(6):463-70. doi: 10.1016/j.neo.2014.05.010. Epub 2014 Jun 20.

41.

[Gastrointestinal stromal tumors: diagnostics and therapy].

Fendrich V, Bartsch DK.

Chirurg. 2014 Jun;85(6):545-56. doi: 10.1007/s00104-013-2681-y. Review. German.

PMID:
24858723
42.

Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors.

Heeger K, Falconi M, Partelli S, Waldmann J, Crippa S, Fendrich V, Bartsch DK.

Langenbecks Arch Surg. 2014 Mar;399(3):315-21. doi: 10.1007/s00423-014-1171-0. Epub 2014 Feb 14.

PMID:
24522434
43.

Enucleation and limited pancreatic resection provide long-term cure for insulinoma in multiple endocrine neoplasia type 1.

Bartsch DK, Albers M, Knoop R, Kann PH, Fendrich V, Waldmann J.

Neuroendocrinology. 2013;98(4):290-8. doi: 10.1159/000357779. Epub 2013 Dec 17.

PMID:
24356648
44.

Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.

Fendrich V, Sparn M, Lauth M, Knoop R, Plassmeier L, Bartsch DK, Waldmann J.

Pancreatology. 2013 Sep-Oct;13(5):502-7. doi: 10.1016/j.pan.2013.08.002. Epub 2013 Aug 20.

PMID:
24075515
45.

RIO kinase 3 acts as a SUFU-dependent positive regulator of Hedgehog signaling.

Tariki M, Wieczorek SA, Schneider P, Bänfer S, Veitinger S, Jacob R, Fendrich V, Lauth M.

Cell Signal. 2013 Dec;25(12):2668-75. doi: 10.1016/j.cellsig.2013.08.037. Epub 2013 Sep 7.

PMID:
24018050
46.

Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.

Plassmeier L, Knoop R, Waldmann J, Kesselring R, Buchholz M, Fichtner-Feigl S, Bartsch DK, Fendrich V.

Langenbecks Arch Surg. 2013 Oct;398(7):989-96. doi: 10.1007/s00423-013-1105-2. Epub 2013 Aug 30.

PMID:
23989613
47.

Familial pancreatic cancer--status quo.

Fendrich V, Langer P, Bartsch DK.

Int J Colorectal Dis. 2014 Feb;29(2):139-45. doi: 10.1007/s00384-013-1760-3. Epub 2013 Aug 16. Review.

PMID:
23948969
48.

Embryonic transcription factors CDX2 and Oct4 are overexpressed in neuroendocrine tumors of the ileum: a pilot study.

Heverhagen AE, Geis C, Fendrich V, Ramaswamy A, Montalbano R, Di Fazio P, Bartsch DK, Ocker M, Quint K.

Eur Surg Res. 2013;51(1-2):14-20. doi: 10.1159/000353612. Epub 2013 Jul 23.

PMID:
23887079
49.

Expression of hedgehog signalling pathway in anaplastic thyroid cancer.

Hinterseher U, Wunderlich A, Roth S, Ramaswamy A, Bartsch DK, Hauptmann S, Greene BH, Fendrich V, Hoffmann S.

Endocrine. 2014 Apr;45(3):439-47. doi: 10.1007/s12020-013-0015-y. Epub 2013 Jul 17.

PMID:
23860623
50.

Shortness: an unknown phenotype of multiple endocrine neoplasia type 1.

López CL, Langer P, Waldmann J, Fendrich V, Sitter H, Nies C, Bartsch DK.

Eur J Endocrinol. 2013 Jul;169(1):133-7.

PMID:
23828958

Supplemental Content

Loading ...
Support Center